Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s1

MANUEL SANTAMARIA OSSORIO2026-01-292026-01-29202210.1007/s10875-022-01219-32-s2.0-85124815559https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/34599ImmunologyImmunology and AllergyCorrection to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s1corrigendum